Transform Your IP

The Station 41 Venture Studio is seeking licensing and commercialization partners to advance biotech products through non-dilutive and equity funding.

Station 41 Venture Studio provides technology programs with the corporate structure and resources to advance further via non-dilutive and equity funding. The Venture Studio was launched by SR in 2022, which implemented a program prioritization rubric using commercial, regulatory, and scientific diligence processes aligned to venture capital standards.

The Venture Studio will launch three cohorts annually, aligned to NIH non-dilutive funding deadlines. In addition to seeding and prioritizing further development of core technologies, the Venture Studio Director and team will launch a business development and marketing function for the spinout entity, including creation of a corporate brand, website, and relevant marketing assets.

Ideal venture studio programs are aligned with Southern Research’s therapeutic development expertise:


  • Small molecules
  • Peptides

Therapeutic Areas

  • Oncology
  • Infectious Disease
  • CNS
  • Chronic Disease
  • Heart & Respiratory

Venture Studio Companies

Contact Us

"*" indicates required fields

Please let us know what's on your mind. Have a question for us? Ask away.